Lithium, benzodiazepines, and sexual function in bipolar patients

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Bipolar disorder treatment often involves lithium and benzodiazepines.
• Limited research exists on the sexual function effects of these medications.
• Assessing drug-induced sexual dysfunction is crucial for patient management.

Purpose of the Study:

• To investigate sexual function in bipolar patients undergoing lithium treatment.
• To determine if lithium, alone or in combination, affects sexual health.
• To explore the impact of benzodiazepine co-administration on sexual function.

Main Methods:

• 104 outpatients with bipolar disorder were assessed using self-rating scales for sexual function.
• Patients were treated with lithium monotherapy or in combination with other psychotropic drugs, including benzodiazepines.
• Serum lithium and plasma prolactin levels were measured, and patients were in a stable euthyroid state.

Main Results:

• Sexual dysfunction was significantly more prevalent in patients receiving lithium combined with benzodiazepines (49%) compared to lithium alone (14%) or other combinations (17%).
• No association was found between serum lithium levels or plasma prolactin concentrations and sexual dysfunction scores.
• Concomitant benzodiazepine use emerged as a key factor associated with sexual dysfunction.

Conclusions:

• Lithium monotherapy appears to have a minimal impact on sexual function in bipolar patients.
• The combination of lithium and benzodiazepines is associated with a high rate of sexual dysfunction.
• Clinicians should proactively address and monitor for drug-induced sexual dysfunction to improve patient compliance and outcomes.